COO Bellete Ambaw receives 107,508 CGON stock options in new grant

Rhea-AI Filing Summary

CG Oncology, Inc. reported that President and COO Bellete Ambaw received a grant of employee stock options. The award covers 107,508 options to buy common stock at an exercise price of $67.68 per share, expiring on April 14, 2036.

According to the footnote, 1/48th of the options vest monthly after the April 15, 2026 vesting commencement date, contingent on Ambaw’s continuous service. Following this grant, Ambaw directly holds 107,508 derivative securities linked to CG Oncology common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bellete Ambaw

Role President and COO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	107,508	$0.00	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 107,508 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 107,508 options Exercise price: $67.68 per share Underlying shares: 107,508 shares +2 more

5 metrics

Options granted 107,508 options Employee stock option grant to President and COO Bellete Ambaw

Exercise price $67.68 per share Conversion or exercise price for the employee stock options

Underlying shares 107,508 shares Underlying CG Oncology common stock linked to the options

Expiration date April 14, 2036 Option expiration for the granted employee stock options

Post-grant derivative holdings 107,508 derivative securities Total options held directly after the reported transaction

Key Terms

Employee Stock Option (Right to Buy), exercise price, vesting commencement date, derivative securities

4 terms

Employee Stock Option (Right to Buy) financial

"security_title: Employee Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 67.6800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting commencement date financial

"vesting commencement date, subject to the Reporting Person's continuous service"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

derivative securities financial

"total_shares_following_transaction: 107508.0000"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bellete Ambaw

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$67.68	04/15/2026		A		107,508		(1)	04/14/2036	Common Stock	107,508	$0	107,508	D

Explanation of Responses:

1. 1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

	/s/ Joshua F. Patterson, Attorney-in-Fact for Ambaw Bellete	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did CGON executive Bellete Ambaw report in this Form 4 filing?

Bellete Ambaw reported receiving an employee stock option grant. The award covers 107,508 options to buy CG Oncology common stock as part of compensation, recorded as an acquisition rather than an open-market purchase or sale.

How many CGON options did Bellete Ambaw receive and at what exercise price?

Bellete Ambaw received 107,508 employee stock options. Each option allows the purchase of one share of CG Oncology common stock at an exercise price of $67.68 per share, providing potential future ownership if exercised.

What is the vesting schedule for Bellete Ambaw’s CGON stock options?

The options vest gradually over time. The filing states that 1/48th of the shares subject to the option vest monthly after April 15, 2026, and vesting continues only while Ambaw maintains continuous service with CG Oncology.

When do Bellete Ambaw’s CGON stock options expire?

The options have a long-dated term. According to the filing, they expire on April 14, 2036, giving Ambaw a multi-year window after vesting to decide whether and when to exercise the options.

How many derivative securities does Bellete Ambaw hold after this CGON grant?

After this transaction, Ambaw directly holds 107,508 derivative securities. These represent the employee stock options granted in the filing, each tied to one underlying share of CG Oncology common stock, subject to vesting and future exercise decisions.